Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 21kWORD 20k
22 August 2019
Answer given by Mr Andriukaitis on behalf of the European Commission
Question reference: E-002161/2019

The Commission is aware of the growing concerns regarding shortages of medicines and the dependence on active substances manufactured in non-EU countries.

To address the security of supply, the Commission, together with the Member States and the European Medicines Agency, is strengthening enforcement and control activities and stimulating the alignment of non-EU countries’ regulatory frameworks with international standards.

The Commission is currently reflecting on possible ways to address these challenges to health security by enhancing oversight of the global manufacturing and supply chain and boosting industrial policy.

In addition, the Heads of Medicines Agencies/European Medicines Agency Task Force is working to develop and coordinate actions to address shortages and availability of medicines. It is currently piloting a system for internal cooperation and information sharing between national authorities. Shortages with an impact on public health are being shared through this system in order to increase awareness and facilitate Member State actions.

Last updated: 28 August 2019Legal notice